Cannabix Technologies Receives Notice of Allowance from CIPO for Contactless Breath Analysis Patent Application
Cannabix Technologies (OTC:BLOZF) has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for its patent application titled "Contact-Free Breath Analysis Device and Method." This follows a similar notice from the U.S. Patent and Trademark Office for the same technology.
The patent covers dual-mode contactless breath capture and analysis technology that can be integrated into vehicles, workplaces, and public kiosks. The system features unmanned testing capabilities, real-time feedback, and intelligent airflow adjustment mechanisms, making it particularly valuable for law enforcement, workplace safety, and public health monitoring applications.
Cannabix Technologies (OTC:BLOZF) ha ricevuto un avviso di concessione dall'Ufficio Canadese per la Propriet脿 Intellettuale (CIPO) per la sua domanda di brevetto intitolata "Dispositivo e Metodo per l'Analisi del Respiro Senza Contatto." Questo segue un avviso simile rilasciato dall'Ufficio Brevetti e Marchi degli Stati Uniti per la stessa tecnologia.
Il brevetto riguarda una tecnologia di cattura e analisi del respiro senza contatto a doppia modalit脿 che pu貌 essere integrata in veicoli, luoghi di lavoro e chioschi pubblici. Il sistema offre capacit脿 di test senza operatore, feedback in tempo reale e meccanismi intelligenti di regolazione del flusso d'aria, risultando particolarmente utile per applicazioni in forze dell'ordine, sicurezza sul lavoro e monitoraggio della salute pubblica.
Cannabix Technologies (OTC:BLOZF) ha recibido un aviso de concesi贸n de la Oficina Canadiense de Propiedad Intelectual (CIPO) para su solicitud de patente titulada "Dispositivo y M茅todo de An谩lisis de Aliento Sin Contacto." Esto sigue a un aviso similar de la Oficina de Patentes y Marcas de Estados Unidos para la misma tecnolog铆a.
La patente cubre una tecnolog铆a de captura y an谩lisis de aliento sin contacto en modo dual que puede integrarse en veh铆culos, lugares de trabajo y quioscos p煤blicos. El sistema cuenta con capacidades de prueba sin operador, retroalimentaci贸n en tiempo real y mecanismos inteligentes de ajuste del flujo de aire, siendo especialmente valioso para aplicaciones en fuerzas del orden, seguridad laboral y monitoreo de la salud p煤blica.
Cannabix Technologies (OTC:BLOZF)電� "牍勳爲齑� 順疙潯 攵勳劃 鞛レ箻 氚� 氚╇矔"鞚措澕電� 韸鬼棃 於滌洂鞐� 雽�頃� 旌愲倶雼� 歆�鞁濎灛靷瓣秾觳�(CIPO)鞙茧攵�韯� 韸鬼棃 項堦皜 韱奠毳� 氚涭晿鞀惦媹雼�. 鞚措姅 霃欖澕 旮办垹鞐� 雽�頃� 氙戈淡 韸鬼棃觳溂搿滊秬韯� 氚涭潃 鞙犾偓頃� 韱奠鞐� 鞚挫潃 瓴冹瀰雼堧嫟.
鞚� 韸鬼棃電� 彀焿, 鞛戩梾鞛� 氚� 瓿店车 韨れ槫鞀ろ伂鞐� 韱淀暕頃� 靾� 鞛堧姅 鞚挫 氇摐 牍勳爲齑� 順疙潯 旌§矘 氚� 攵勳劃 旮办垹鞚� 韽暔頃╇媹雼�. 鞚� 鞁滌姢韰滌潃 氍挫澑 瓴�靷� 旮半姤, 鞁れ嫓臧� 頂茧摐氚� 氚� 歆�電ロ槙 瓿店赴 頋愲 臁办爤 氅旍护雼堨鞚� 臧栰稊瓿� 鞛堨柎 氩� 歆戫枆, 鞛戩梾鞛� 鞎堨爠 氚� 瓿奠 氤搓贝 氇媹韯半鞐� 韸鬼瀳 鞙犾毄頃╇媹雼�.
Cannabix Technologies (OTC:BLOZF) a re莽u un avis d'acceptation de l'Office de la propri茅t茅 intellectuelle du Canada (CIPO) pour sa demande de brevet intitul茅e "Dispositif et m茅thode d'analyse de l'haleine sans contact." Ceci fait suite 脿 un avis similaire de l'Office des brevets et des marques des 脡tats-Unis concernant la m锚me technologie.
Le brevet couvre une technologie d'analyse de l'haleine sans contact 脿 double mode pouvant 锚tre int茅gr茅e dans les v茅hicules, les lieux de travail et les kiosques publics. Le syst猫me propose des capacit茅s de test sans op茅rateur, un retour en temps r茅el et des m茅canismes intelligents d'ajustement du flux d'air, ce qui le rend particuli猫rement utile pour les applications en forces de l'ordre, s茅curit茅 au travail et surveillance de la sant茅 publique.
Cannabix Technologies (OTC:BLOZF) hat vom Canadian Intellectual Property Office (CIPO) eine Zulassungsmitteilung f眉r seine Patentanmeldung mit dem Titel "Kontaktloses Atemanalyseger盲t und -verfahren" erhalten. Dies folgt auf eine 盲hnliche Mitteilung des US-Patent- und Markenamts f眉r dieselbe Technologie.
Das Patent umfasst eine dualmodale kontaktlose Atemerfassung- und Analysetechnologie, die in Fahrzeuge, Arbeitspl盲tze und 枚ffentliche Kioske integriert werden kann. Das System bietet unbemannte Testm枚glichkeiten, Echtzeit-Feedback und intelligente Luftstromanpassungsmechanismen, was es besonders wertvoll f眉r Anwendungen in Strafverfolgung, Arbeitssicherheit und 枚ffentlicher Gesundheits眉berwachung macht.
- Patent approval strengthens intellectual property portfolio in breath analysis technology
- Technology has multiple commercial applications across law enforcement, workplace safety, and public health
- Dual-mode system offers both contactless and traditional mouthpiece options
- Received patent allowance in both U.S. and Canadian markets
- Patent fees still need to be paid to complete the grant process
- No immediate revenue generation mentioned from the technology
VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the 鈥淐ompany or Cannabix鈥�) is pleased to report that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for patent application No. 3243445 entitled, 鈥淐ontact-Free Breath Analysis Device and Method鈥� to the Company. Recently the U.S.聽Patent聽and Trademark Office issued a notice of allowance for the same patent application filed in the United States. A notice of allowance indicates that the patent application has been approved by an examiner and that the Company can move forward with obtaining the patent granted upon payment of certain fees fee within a specified timeframe.
This patent application is centered on innovations made by Cannabix and its dual mode contactless (and traditional mouthpiece) breath capture and analysis technology. The technology has wide-ranging utility and can be integrated into everyday environments such as vehicles, workplaces, or public kiosks and supports fast, reliable testing without requiring physical contact. The technology can be used in unmanned breath devices, offering real-time feedback through visual indicators and displays and is well-suited for applications in law enforcement, workplace safety, and public health monitoring. The system intelligently adjusts its internal airflow and pump mechanisms based on the sampling method, ensuring accurate and hygienic analysis.
This patent application continues to augment Cannabix鈥檚 leadership position at the forefront of breath sampling and detection techniques and continues to grow the intellectual capital of Cannabix鈥檚 breath capture and analytics portfolio. The Company will report on future material developments regarding its 鈥淐ontact-Free Breath Analysis Device and Method鈥� patent applications in due course.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring
We seek Safe Harbor.
On behalf of the Board of Directors
鈥淩av Mlait鈥�
CEO
Cannabix Technologies Inc.
For further information, contact the Company at [email protected]
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain 鈥渇orward-looking statements鈥� within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as 鈥渁nticipates,鈥� 鈥減lan,鈥� 鈥渃ontinue,鈥� 鈥渆xpect,鈥� 鈥減roject,鈥� 鈥渋ntend,鈥� 鈥渂elieve,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥減otential,鈥� 鈥減roposed,鈥� 鈥減ositioned鈥� and other similar words, or statements that certain events or conditions 鈥渕ay鈥� or 鈥渨ill鈥� occur. Forward-looking statements in this news release include, but are not limited to, statements relating to patent applications described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company鈥檚 plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that patent applications are not awarded by regulatory authorities; that the CSE may not approve the issuance of the securities; that the Company鈥檚 development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any 鈥減atent pending鈥� or 鈥減rovisional patents鈥� technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
FAQ
What patent did Cannabix Technologies (BLOZF) receive approval for in July 2025?
How does Cannabix Technologies' contactless breath analysis technology work?
What are the main applications for Cannabix Technologies' breath analysis system?
Where can Cannabix Technologies' breath analysis system be installed?
Has Cannabix Technologies received patent approval in the United States?
